At the time of writing, Unity Biotechnology Inc [UBX] stock is trading at $1.78, up 39.06%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The UBX shares have gain 78.18% over the last week, with a monthly amount glided 58.93%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Unity Biotechnology Inc [NASDAQ: UBX] stock has seen the most recent analyst activity on August 22, 2024, when Rodman & Renshaw initiated its Buy rating and assigned the stock a price target of $8. Previously, Wedbush upgraded its rating to Outperform on November 16, 2023, and elevated its price target to $4. On January 04, 2022, upgrade upgraded it’s rating to Buy. Mizuho upgraded its rating to a Buy and increased its price target to $7 on November 10, 2021. Citigroup upgraded its rating to a Buy but $6 remained the price target by the analyst firm on June 28, 2021. H.C. Wainwright started tracking with a Buy rating for this stock on June 07, 2021, and assigned it a price target of $12. In a note dated February 16, 2021, Citigroup downgraded an Sell rating on this stock and boosted its target price from $5 to $6.
For the past year, the stock price of Unity Biotechnology Inc fluctuated between $0.94 and $2.02. Unity Biotechnology Inc [NASDAQ: UBX] shares were valued at $1.78 at the most recent close of the market.
Analyzing the UBX fundamentals
Gross Profit Margin for this corporation currently stands at 0.53% with Operating Profit Margin at -17.22%, Pretax Profit Margin comes in at -11.51%, and Net Profit Margin reading is -11.51%. To continue investigating profitability, this company’s Return on Assets is posted at -0.46, Equity is -1.01 and Total Capital is -0.85.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.4300 points at the first support level, and at 1.0800 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.0500, and for the 2nd resistance point, it is at 2.3200.
Ratios To Look Out For
It is important to note that Unity Biotechnology Inc [NASDAQ:UBX] has a current ratio of 3.45. Also, the Quick Ratio is 3.45, while the Cash Ratio stands at 1.01.
Transactions by insiders
Recent insider trading involved Ghosh Anirvan, Chief Executive Officer, that happened on Nov 04 ’24 when 432.0 shares were sold. CFO & Head of Corp. Dev., Sullivan Lynne Marie completed a deal on Nov 04 ’24 to sell 136.0 shares. Meanwhile, Chief Legal Officer Nguyen Alexander Hieu sold 149.0 shares on Nov 04 ’24.
